New formulation of prostate drug put to the test in healthy volunteers
NCT ID NCT07643220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new formulation (AJU-G721) of a drug used for benign prostatic hyperplasia (BPH) to the original version (G721R) in healthy adult men. The goal is to see if the two versions are absorbed and processed by the body in the same way. Participants receive a single dose of each version on separate occasions, and their blood is tested to measure drug levels. This is a standard step before the new formulation can be considered for use in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dutasteride and Tamsulosin (combination drug)
- What this could lead to
- If the new formulation is shown to be equivalent, it could offer a more affordable or accessible treatment option for men with enlarged prostate.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients, so results may not directly predict effectiveness or safety in the target population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE BENIGN PROSTATIC HYPERPLASIA (BPH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bumin Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.